Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 20Unknown 6Terminated 2Withdrawn 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Leukemia, Myeloid, Acute 18Recurrence 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Leukemia, Monocytic, Acute 6Prostatic Neoplasms 5Leukemia, Myelomonocytic, Acute 5Leukemia, Megakaryoblastic, Acute 5Leukemia, Erythroblastic, Acute 5Leukemia 5Congenital Abnormalities 4Lymphoma, Follicular 3Myelodysplastic Syndromes 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma 2Leukemia, Lymphocytic, Chronic, B-Cell 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Pain 1Ovarian Neoplasms 1Neoplasms, Plasma Cell 1Neoplasms 1Myeloid Malignancies 1Multiple Myeloma 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, T-Cell 1Leukemia, Myelomonocytic, Juvenile 1Leukemia, Eosinophilic, Acute 1Leukemia, Biphenotypic, Acute 1Leukemia, Basophilic, Acute 1

Interventions

Rituximab 66Cyclophosphamide 52fludarabine phosphate 26fludarabine 22Filgrastim 21Vincristine 19Methotrexate 19Melphalan 19Doxorubicin 18Radiotherapy 17Etoposide 17Prednisone 16Tacrolimus 15Whole-Body Irradiation 14Mycophenolic Acid 14Cytarabine 14Peripheral Blood Stem Cell Transplantation 13Gemcitabine 13Cyclosporine 13Antilymphocyte Serum 13Lenalidomide 12Busulfan 11Bortezomib 11Granulocyte Colony-Stimulating Factor 9Alemtuzumab 9sargramostim 8Dexamethasone 8Cord Blood Stem Cell Transplantation 8pembrolizumab 7ibritumomab tiuxetan 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Lymphoma × Mitoxantrone × Clear all
NCT00901927 2020-04-03

Bendamustine, Mitoxantrone, and Rituximab (BMR) for Patients With Untreated High Risk Follicular Lymphoma

M.D. Anderson Cancer Center

Phase 2 Terminated
14 enrolled 10 charts
Lymphoid

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin

NCT00208975 2012-06-28

Phase II Study of Fludarabine and Mitoxantrone, Followed by GM-CSF(Granulocyte-macrophage Colony-stimulating Factor) and Rituximab

Emory University

Phase 2 Terminated
15 enrolled 5 charts
Lymphoid

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡